11/19
04:30 pm
abvx
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
Low
Report
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
11/14
04:01 pm
abvx
Abivax presents third quarter 2024 key financial information
Medium
Report
Abivax presents third quarter 2024 key financial information
11/13
04:01 pm
abvx
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
Low
Report
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
10/7
04:01 pm
abvx
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
Medium
Report
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
10/3
04:01 pm
abvx
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
Medium
Report
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
10/3
02:31 am
abvx
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
Low
Report
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
9/26
02:30 am
abvx
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
Medium
Report
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
9/25
04:01 pm
abvx
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
Medium
Report
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
9/9
04:01 pm
abvx
Abivax presents first-half 2024 financial results
Low
Report
Abivax presents first-half 2024 financial results